İdiyopatik Santral Erken Ergenlik Tanılı Bir Grup Hastanın Başvuru ve Büyüme Özellikleri

Yıl 2021, , 277 - 281, 27.09.2021

Şeyma Sönmez Şahin , Ayla Güven

https://doi.org/10.21673/anadoluklin.815696

Öz

Amaç: Bu çalışmada idiyopatik santral erken ergenlik (SEE) tanılı hastalarda etiyoloji, prognoz, klinik özellikler ve tedavi yanıtı üzerine bir değerlendirme amaçlanmıştır.
Yöntem: Çocuk endokrinoloji polikliniğimizde Haziran 2001—Eylül 2015 döneminde idiyopatik SEE tanısı konmuş olan toplam 175 hastanın tıbbi kayıtları geriye dönük olarak incelenmiştir.
Bulgular: Hastaların büyük kısmı kız ve 6 yaşından büyük idi. Gonadotropin salgılatıcı hormon analogları ile tedavinin kilo aldırmadığı, erken başvuru ve erken tedavi ile öngörülen boyda artış sağlandığı saptandı.
Sonuç: İdiyopatik SEE’li hastalarda erken tanı ve tedavi büyüme potansiyelinin korunmasında önemli bir rol oynamaktadır.

Anahtar Kelimeler

erken ergenlik, erken ergenlik tedavisi, gonadotropin salgılatıcı hormon analogları, hedef boy, öngörülen boy

The Admission and Growth Characteristics of a Group of Patients Diagnosed with Idiopathic Central Precocious Puberty

Öz

Aim: In this study, we aimed to evaluate the etiology, prognosis, clinical characteristics, and treatment response in patients diagnosed with idiopathic central precocious puberty (CPP).
Methods: We retrospectively reviewed the medical records of a total of 175 patients who were diagnosed with idiopathic CPP at our pediatric endocrinology outpatient clinic between June 2001 and September 2015.
Results: Most of the patients were girls and older than 6 years of age. We found that treatment with gonadotropin-releasing hormone analogues did not cause weight gain, and that younger age at admission and early treatment resulted in an increase in predicted height.
Conclusion: Early diagnosis and treatment play an important role in the preservation of growth potential in patients with idiopathic CPP.

Anahtar Kelimeler

gonadotropin-releasing hormone analogues, precocious puberty, precocious puberty treatment, predicted height, target height

Kaynakça

• Terasawa E, Fernandez DL. Neurobiological mechanisms of the onset of the puberty in primates. Endocr Rev. 2001;22:111–51.
• Wheeler MD. Physical changes of puberty. Endocrinol Metab Clin North Am. 1991;20:1–14.
• Lee PA, Houk CP. Puberty and its disorders. In: Lifshitz F (ed.), Pediatric Endocrinology, 5. ed. Londra: Informa Healthcare; 2007:272–303.
• Ebling FJ. The neuroendocrine timing of puberty. Reproduction. 2005;129:675–83.
• Partsch CJ, Heger S, Sippel WG. Management and outcome central precocious puberty. Clin Endocrinol. 2002;56:129–48.
• Comite F, Cassoria F, Barnes KM, Hench KD, Dwyer A, Skerda MC, ve ark. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty: long term effect on somatic growth, bone maturation and predicted height. JAMA. 1986;255:2613–6.
• Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr. Adult height in precocious puberty after long term treatment with doslorelin. J Clin Endocrinol Metab. 1991;73:1235–40.
• Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol. 2008;159(ek 1):S3–8.
• Anasti JN, Flack MR, Froclich J. A potential novel mechanism of precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab. 1995;80:276–9.
• Tanner JM, Whitehouse RH, Marubini E, Resele LF. The adolescent growth spurt of boys and girls of the Harpenden growth study. Ann Hum Biol. 1976;3:109–26.
• Alikaşifoğlu A, Vuralli D, Gonc EN. Changing etiological trends in male precocious puberty: evalution of 100 cases wih central precocious puberty over the last decade. Horm Res Paediatr. 2015;83:340–4.
• Gaibicani E, Allali S, Durand A, Sommet J, Couto-Silva AC, Brauner R. Presentation of 493 consecutive girls with idiopathic central precocious puberty: a single center study. PloS One. 2013;8(7):e70931.
• Ibanez L, de Zegher F. Puberty after prenatal growth restraint. Horm Res. 2006;65(ek 3):112–5.
• Trivin C, Couta-Silva AC, Sainte-Rose C, Chemaitilly W. Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. Clin Endocrinol. 2001;54:289–94.
• Wolters B, Lass N, Reinehr T. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children. Horm Res Paediatr. 2012;78:304–11.
• van der Sluis IM, Boot AM, Krenning EP, Drop SLS, Keizer-Schrama SMPFM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin End Met. 2002;87:506–12.
• Pasquino AM, Pucarelli I, Passeri F, Segni M, Mancini MA, Municchi G. Progression of premature thelarche to central precocious puberty. J Pediatr. 1995;126:11–4.
• Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Human Repr Update. 2004;10(2):135–47.